The Venture Codex

Led · Equity · Jun 2025

Glytec provides an AI-based technology platform for diabetes and related conditions, centered on its flagship Glucommander cloud-based SaaS for inpatient glycemic management. Glucommander is trusted by 400+ hospitals nationwide to improve patient safety, reduce costs, and shorten lengths of stay. The company plans to expand its platform and advance the development of new technologies addressing diabetes and related comorbidities. It intends to support hospitals in complying with upcoming CMS quality measures for inpatient glycemic control. Glytec emphasizes precision insulin management and data-driven insights to help clinicians individualize care and optimize metabolic health outcomes. The company has closed a $36 million growth investment to scale R&D, expand the platform, and support rapid response to regulatory requirements. Glytec’s core product is the FDA-cleared Glucommander eGlycemic Management System, a software platform that delivers personalized, endocrinologist-level insulin dosing across the hospital-to-home continuum. The eGMS is integrated with EHRs to track blood glucose data, detect glycemic disarray, provide personalized dosing regimens, and accelerate patients into target glucose ranges. Clinical validation includes more than 90 research studies and reported reductions such as a 99.8% decrease in low blood sugar, 36–68% lower 30-day readmissions, and length-of-stay reductions up to 3.2 days. Customers report enterprise-wide utilization at or above 95% of eligible patients, annualized cost savings up to $20,000 per licensed bed, and deployment at more than 300 U.S. hospitals including AdventHealth, Novant Health and Sentara Healthcare. Glytec plans to invest in R&D around patient safety, provider workflows, and analytics, expand integrations with EHRs, mobile apps and other diabetes technologies, and grow headcount to scale its flagship product. The company is headquartered outside of Boston (Waltham, Mass.).

Led · Series B · Sep 2019

OncoCell MDx is a privately held immunogenomics platform company developing and commercializing noninvasive blood-based assays designed to aid physicians in understanding disease pathology in prostate cancer and other diseases. Its proprietary immunogenomics technology, developed at Harvard Medical School by founder Professor Amin I. Kassis, uses RNA-Seq–based signatures to discriminate healthy patients from those with indolent versus aggressive disease. The company has built a database of over 2,000 patient subjects analyzed with RNA-Seq to identify those signatures. OncoCell plans to launch a blood test for detection and grading of aggressive prostate cancer next year. The company has raised more than $30 million to date and said the new financing will bolster its balance sheet and support ongoing development and commercialization of its pan-disease diagnostic platform. By enabling serial noninvasive testing, the company aims to help rule out disease progression, reduce cost of care, and improve quality of life.

Led · Equity · May 2018

Ancora Heart develops the AccuCinch® Ventricular Restoration System, a completely transcatheter device intended to restore the structure and function of an enlarged left ventricle in patients with heart failure with reduced ejection fraction (HFrEF). The AccuCinch implant is attached to the inner wall of the left ventricle to reduce its size, lower wall stress, and support the heart wall with the goal of reducing symptoms and improving quality of life. The AccuCinch System is investigational and is being evaluated in multiple clinical trials in the U.S. and EU, including the pivotal CORCINCH-HF trial and the CORCINCH-EU study. The CORCINCH-HF study is designed to enroll 400 patients at up to 80 centers worldwide with an initial analysis for PMA submission after the first 250 patients reach six months of follow-up. Ancora plans to use recent financing to accelerate the CORCINCH-HF pivotal study and to prepare for potential FDA PMA submission, launch, and commercialization. Ancora Heart is a privately held company based in Santa Clara, Calif. Ancora Heart is developing the AccuCinch Ventricular Repair System, a minimally invasive investigational treatment for heart failure and functional mitral regurgitation. The AccuCinch procedure is intended to directly repair the enlarged left ventricle, reduce ventricular size, improve left ventricular function, and restore proper mitral valve function. The therapy is aimed at patients whose disease has progressed beyond management with medications or pacemakers or who face high risk from open-heart surgery. Ancora has reported encouraging early clinical results and engagement from leading heart centers participating in studies of the system. The company plans to use new financing to support clinical trials evaluating safety and efficacy and to continue product development. Ancora Heart is based in Santa Clara, Calif.

Participated · Series C · Dec 2014

Naurex is a clinical-stage biopharmaceutical company based in Evanston, Ill., that has built a platform to discover drugs that enhance synaptic plasticity via selective modulation of the NMDA receptor. Its lead molecule, GLYX-13, has demonstrated rapid, robust and sustained antidepressant effects in multiple Phase 2 studies and was well-tolerated in clinical proof-of-concept studies. Naurex is proceeding with a GLYX-13 Phase 3 program after completing an end-of-Phase 2 meeting with the FDA and expects Phase 3 to begin in 2015. The company’s next-generation oral candidate, NRX-1074, is in Phase 2 for major depressive disorder and has shown promising preclinical efficacy and early clinical tolerability. Naurex applies its NMDA-focused platform to generate a pipeline of subtype-selective modulators aimed at a range of CNS indications, including depression, traumatic brain injury and neuropathic pain. The company planned to use financing proceeds to support ongoing clinical development of GLYX-13, NRX-1074 and related development activities across its pipeline. Naurex is a clinical-stage company based in Evanston, Illinois, developing drugs that modulate the NMDA receptor for psychiatry and neurology. Its lead program is GLYX-13, an NMDA receptor modulator in development for the treatment of depression. The company is also advancing its second-generation compound NRX-1074 into Phase I and II clinical trials in depression. Naurex plans to further develop its second- and third-generation programs for other CNS disorders. Leadership includes CEO Derek A. Small and executive chairman Bill Gantz, and the company’s programs are based on work by founder Dr. Joseph R. Moskal and colleagues at Northwestern University. Financially, Naurex completed a $38M Series B financing to fund these development programs. Naurex, based in Evanston, IL, is a clinical-stage company focused on therapeutics for psychiatry and neurology. Its lead compound is GLYX-13, a glycine-site functional partial agonist (GFPA) selective modulator of the NMDA receptor. GLYX-13 showed promising antidepressant activity and excellent safety in preclinical studies, results that were confirmed in a Phase I clinical trial. The company plans a Phase II trial targeting patients not achieving an adequate response to current antidepressants. Naurex is also advancing a second-generation GFPA program with multiple molecules showing preclinical proof of concept. The company is led by CEO Derek A. Small and has made recent board appointments including Wilbur (Bill) Gantz as chairman, with Terry Gould and Kenneth Widder joining the board.

Participated · Series D · Sep 2010

Solaria raised $30 million in financing, according to Securities and Exchange Commission filings. The filings indicate there was only one investor in the offering. The company is backed by investors including CMEA Capital, DBL Investors, Mitsui Ventures, Savitr Capital, Sigma Partners and NGEN Partners. Solaria previously closed a $45 million Series D round in 2010. Solaria Corporation manufactures photovoltaic (PV) modules and systems for large and utility-scale tracking applications, with modules available separately or as complete tracking systems. The article lists the company as Solaria Inc./Solaria Corporation and cites Fremont, CA. Solaria Corporation is a Fremont, California–based global manufacturer of solar photovoltaic modules. The company produces patented solar PV modules intended for solar system integrators, project developers and electric utilities. Solaria plans to use new funding to accelerate production of its patented modules. It raised an additional $20M to its Series D, bringing the round to $65M, which includes a $10M growth loan facility. Investors in the close include Adams Street Partners, Cycad Group, Western Technologies, CMEA Capital, DBL Investors, Sigma Partners, NGEN Partners, Mitsui Ventures, Savitr Capital and enXco. The company intends to make its modules available across North America, Europe and Asia.